Biofil Chemicals Pharmaceuticals Ltd vs Krebs Biochemicals Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Biofil Chemicals & Pharmaceuticals Ltd is ₹ 32.22 as of 18 May 15:30 . The P/E Ratio of Biofil Chemicals & Pharmaceuticals Ltd changed from 86.4 on March 2021 to 121 on March 2025 . This represents a CAGR of 6.97% over 5 yearsThe P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 106.81 crore on March 2021 to ₹ 66.92 crore on March 2025 . This represents a CAGR of -8.93% over 5 yearsThe Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 174.33 crore on March 2021 to ₹ 144 crore on March 2025 . This represents a CAGR of -3.75% over 5 years The revenue of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.93 crore as compare to the Sep '25 revenue of ₹ 13.6 crore. This represent the decline of -93.16% The revenue of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 7.28 crore as compare to the Sep '25 revenue of ₹ 4.17 crore. This represent the growth of 74.58% The ebitda of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.17 crore as compare to the Sep '25 ebitda of ₹ 0.18 crore. This represent the decline of -5.56% The ebitda of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0.3 crore as compare to the Sep '25 ebitda of ₹ -2.79 crore. This represent the decline of -110% The net profit of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0.08 crore over 7 quarters. This represents a CAGR of -35.00% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ -5.17 crore to ₹ -3.13 crore over 7 quarters. This represents a CAGR of -24.93% The Dividend Payout of Biofil Chemicals & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Limited (BCPL) was incorporated as a Private Limited Company on 4 Jan.'85 for manufacturing and trading of Pharmaceuticals products.
Later on, the Company was converted into a Public Limited Company on 7 May '92.
The Company deals in providing job work facility in respect of manufacturing of pharmaceuticals drug.
It runs the business via two unit viz Pharmaceutical Division & Chemicals Division. In Feb.'96, the company had come out with a rights-cum-public issue at a premium of Rs 7.50 and at a premium of Rs 12.50 respectively, both aggregating Rs 23.21 cr, to part-finance its expansion and diversification into bulk drugs and pharmaceutical formulations.
The company currently manufactures pharmaceutical formulations like injections, capsules, eye-drops and dry syrups at its plant located in Indore.

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991.
The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003.
Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA.

FAQs for the comparison of Biofil Chemicals & Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd

Which company has a larger market capitalization, Biofil Chemicals & Pharmaceuticals Ltd or Krebs Biochemicals & Industries Ltd?

Market cap of Biofil Chemicals & Pharmaceuticals Ltd is 52 Cr while Market cap of Krebs Biochemicals & Industries Ltd is 124 Cr

What are the key factors driving the stock performance of Biofil Chemicals & Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd?

The stock performance of Biofil Chemicals & Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biofil Chemicals & Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd?

As of May 18, 2026, the Biofil Chemicals & Pharmaceuticals Ltd stock price is INR ₹32.21. On the other hand, Krebs Biochemicals & Industries Ltd stock price is INR ₹57.85.

How do dividend payouts of Biofil Chemicals & Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd compare?

To compare the dividend payouts of Biofil Chemicals & Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.